Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 373

1.

Twenty-Five Years of The Oncologist.

Chabner BA.

Oncologist. 2020 Jan;25(1):1-2. doi: 10.1634/theoncologist.2019-0883. Epub 2019 Dec 13. No abstract available.

2.

POETIC (Program for Enhanced Training in Cancer): An Initial Experience of Supporting Capacity Building for Oncology Training in Sub-Saharan Africa.

Fish M, Parkes J, Dharsee N, Dryden-Peterson S, Efstathiou J, Schnipper L, Chabner BA, Parikh AR.

Oncologist. 2019 Dec;24(12):1557-1561. doi: 10.1634/theoncologist.2019-0207. Epub 2019 Jun 10.

3.

Addressing the Financial Burden of Cancer Clinical Trial Participation: Longitudinal Effects of an Equity Intervention.

Nipp RD, Lee H, Gorton E, Lichtenstein M, Kuchukhidze S, Park E, Chabner BA, Moy B.

Oncologist. 2019 Aug;24(8):1048-1055. doi: 10.1634/theoncologist.2019-0146. Epub 2019 Apr 15.

4.

Immuno-Oncology in China.

Lu S, Chabner BA.

Oncologist. 2019 Feb;24(Suppl 1):S1-S2. doi: 10.1634/theoncologist.2019-IO-S1-edi.

5.

The Other Opioid Crisis: Just Another Drug Shortage?

Soumerai TE, Kamdar MM, Chabner BA.

Oncologist. 2019 May;24(5):574-575. doi: 10.1634/theoncologist.2018-0514. Epub 2019 Feb 28.

6.

Cell-free DNA Analysis in Cancer.

Corcoran RB, Chabner BA.

N Engl J Med. 2019 Jan 31;380(5):501-502. doi: 10.1056/NEJMc1816154. No abstract available.

PMID:
30699310
7.

Application of Cell-free DNA Analysis to Cancer Treatment.

Corcoran RB, Chabner BA.

N Engl J Med. 2018 Nov 1;379(18):1754-1765. doi: 10.1056/NEJMra1706174. Review. No abstract available.

PMID:
30380390
8.

Conflict of Interest: An Ethical Firestorm with Consequences for Cancer Research.

Chabner BA, Bates SE.

Oncologist. 2018 Dec;23(12):1391-1393. doi: 10.1634/theoncologist.2018-0662. Epub 2018 Oct 23.

9.

Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana.

Milligan MG, Bigger E, Abramson JS, Sohani AR, Zola M, Kayembe MKA, Medhin H, Suneja G, Lockman S, Chabner BA, Dryden-Peterson SL.

J Glob Oncol. 2018 Sep;4:1-11. doi: 10.1200/JGO.17.00084.

10.

Canakinumab and Lung Cancer: Intriguing, but Is It Real?

Chabner BA, Nabel CS.

Oncologist. 2018 Jun;23(6):637-638. doi: 10.1634/theoncologist.2018-0116. Epub 2018 Apr 17. No abstract available.

11.

Does Chemotherapy Induce Metastases?

Chabner BA.

Oncologist. 2018 Mar;23(3):273-274. doi: 10.1634/theoncologist.2017-0648. No abstract available.

12.

Considerations About the Use of Biomarkers in Cancer Clinical Trials.

Chabner BA.

Clin Pharmacol Ther. 2018 Jan;103(1):25-27. doi: 10.1002/cpt.895. Epub 2017 Nov 14.

PMID:
29134628
13.

On Losing Paddy Johnston.

Chabner BA.

Oncologist. 2017 Aug;22(8):1014. doi: 10.1634/theoncologist.2017-0323. Epub 2017 Jul 27. No abstract available.

14.

Regarding "Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies".

Chabner BA.

Oncologist. 2017 Jul;22(7):757-758. doi: 10.1634/theoncologist.2017-0202. Epub 2017 Jun 2. No abstract available.

15.

Advantages of a Truly Open-Access Data-Sharing Model.

Bertagnolli MM, Sartor O, Chabner BA, Rothenberg ML, Khozin S, Hugh-Jones C, Reese DM, Murphy MJ.

N Engl J Med. 2017 Mar 23;376(12):1178-1181. doi: 10.1056/NEJMsb1702054. No abstract available.

PMID:
28328337
16.

Let This Be Our New Year's Pledge.

Chabner BA, Murphy MJ.

Oncologist. 2017 Jan;22(1):1-2. doi: 10.1634/theoncologist.2017-0001. No abstract available.

17.

Limits to Precision Cancer Medicine.

Clark JW, Chabner BA.

N Engl J Med. 2017 Jan 5;376(1):96. doi: 10.1056/NEJMc1613563. No abstract available.

PMID:
28052223
18.

Understanding the Precision in "Precision Medicine".

Chabner BA.

Oncologist. 2016 Sep;21(9):1029-30. doi: 10.1634/theoncologist.2016-0278. Epub 2016 Aug 26. No abstract available.

19.

Holographic Assessment of Lymphoma Tissue (HALT) for Global Oncology Field Applications.

Pathania D, Im H, Kilcoyne A, Sohani AR, Fexon L, Pivovarov M, Abramson JS, Randall TC, Chabner BA, Weissleder R, Lee H, Castro CM.

Theranostics. 2016 Jun 18;6(10):1603-10. doi: 10.7150/thno.15534. eCollection 2016.

20.

While We're at It, Let's Whack the FDA.

Chabner BA.

Oncologist. 2016 Mar;21(3):259-60. doi: 10.1634/theoncologist.2016-0041. Epub 2016 Feb 11. No abstract available.

21.

Reflections on 2015.

Chabner BA.

Oncologist. 2016 Feb;21(2):129-30. doi: 10.1634/theoncologist.2016-0005. Epub 2016 Jan 19. No abstract available.

22.

NCI-60 Cell Line Screening: A Radical Departure in its Time.

Chabner BA.

J Natl Cancer Inst. 2016 Jan 11;108(5). pii: djv388. doi: 10.1093/jnci/djv388. Print 2016 May.

PMID:
26755050
23.

A Roadmap for a New Academic Pathway for Global Radiation Oncology.

Olson AC, Coleman CN, Hahn SM, DeWeese TL, Shulman LN, Chabner BA, Chao N, Martei YM, Mundt AJ, Grover S.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):493-6. doi: 10.1016/j.ijrobp.2015.06.023. No abstract available.

PMID:
26460990
24.

Improving Prospects for Targeting RAS.

Singh H, Longo DL, Chabner BA.

J Clin Oncol. 2015 Nov 1;33(31):3650-9. doi: 10.1200/JCO.2015.62.1052. Epub 2015 Sep 14. Review.

PMID:
26371146
25.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.

Mayo Clin Proc. 2015 Aug;90(8):996-1000. doi: 10.1016/j.mayocp.2015.06.001. Epub 2015 Jul 23. No abstract available.

26.

Breakthrough Drugs and Turtle Soup.

Chabner BA.

Oncologist. 2015 Aug;20(8):845-6. doi: 10.1634/theoncologist.2015-0247. Epub 2015 Jul 16. No abstract available.

27.

Ponatinib: Accelerated Disapproval.

Gainor JF, Chabner BA.

Oncologist. 2015 Aug;20(8):847-8. doi: 10.1634/theoncologist.2015-0253. Epub 2015 Jul 14. No abstract available.

28.

Two decades of the oncologist.

Chabner BA.

Oncologist. 2015 Jan;20(1):1-2. doi: 10.1634/theoncologist.2014-0490. No abstract available.

29.

Patient navigation based on predictive modeling decreases no-show rates in cancer care.

Percac-Lima S, Cronin PR, Ryan DP, Chabner BA, Daly EA, Kimball AB.

Cancer. 2015 May 15;121(10):1662-70. doi: 10.1002/cncr.29236. Epub 2015 Jan 13.

30.

Defining a new role for the National Cancer Institute cooperative groups: more science, fewer trials.

Chabner BA.

Oncologist. 2014 Nov;19(11):1113-4. doi: 10.1634/theoncologist.2014-0359. Epub 2014 Oct 17. No abstract available.

31.

Addressing the growing cancer burden in the wake of the AIDS epidemic in Botswana: The BOTSOGO collaborative partnership.

Efstathiou JA, Bvochora-Nsingo M, Gierga DP, Alphonse Kayembe MK, Mmalane M, Russell AH, Paly JJ, Brown C, Musimar Z, Abramson JS, Bruce KA, Karumekayi T, Clayman R, Hodgeman R, Kasese J, Makufa R, Bigger E, Suneja G, Busse PM, Randall TC, Chabner BA, Dryden-Peterson S.

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):468-75. doi: 10.1016/j.ijrobp.2014.03.033.

32.

Pharmacodynamic biomarkers: falling short of the mark?

Gainor JF, Longo DL, Chabner BA.

Clin Cancer Res. 2014 May 15;20(10):2587-94. doi: 10.1158/1078-0432.CCR-13-3132. Review.

33.

Approval after phase I: ceritinib runs the three-minute mile.

Chabner BA.

Oncologist. 2014 Jun;19(6):577-8. doi: 10.1634/theoncologist.2014-0143. Epub 2014 May 1. No abstract available.

34.

Effective double whammy targets DNA synthesis in leukemia.

Chabner BA.

J Exp Med. 2014 Mar 10;211(3):384. doi: 10.1084/jem.2113insight1. No abstract available.

35.

Announcing a new section: Global health and cancer.

Knaul FM, Chabner BA.

Oncologist. 2013;18 Suppl:1-2. doi: 10.1634/theoncologist.18-S2-1. No abstract available.

36.

Clinical trial results: Sharing results, speeding discoveries.

Fojo AT, Bates SE, Chabner BA.

Oncologist. 2013;18(7):779. doi: 10.1634/theoncologist.2013-0247. No abstract available.

37.

Cancer in Botswana: the second wave of AIDS in Sub-Saharan Africa.

Chabner BA, Efstathiou J, Dryden-Peterson S; visiting team from the Massachusetts General Hospital Cancer Center and our partners at the Medical School of the University of Botswana, the Princess Marina Hospital, the Gaborone Private Hospital, and the Botswana Ministry of Health.

Oncologist. 2013;18(7):777-8. doi: 10.1634/theoncologist.2013-0218. No abstract available.

38.

Personalized medicine: hype or reality.

Chabner BA, Ellisen LW, Iafrate AJ.

Oncologist. 2013 Jun;18(6):640-3. doi: 10.1634/theoncologist.2013-0210. No abstract available.

39.

In this issue: personalized medicine.

Chabner BA.

Oncologist. 2013 Jun;18(6):639. doi: 10.1634/theoncologist.2013-0211. No abstract available.

40.

The impact of a culturally tailored patient navigator program on cervical cancer prevention in Latina women.

Percac-Lima S, Benner CS, Lui R, Aldrich LS, Oo SA, Regan N, Chabner BA.

J Womens Health (Larchmt). 2013 May;22(5):426-31. doi: 10.1089/jwh.2012.3900. Epub 2013 Apr 26.

41.

ERBB2 inhibition and heart failure.

Cote GM, Sawyer DB, Chabner BA.

N Engl J Med. 2013 Feb 28;368(9):876. doi: 10.1056/NEJMc1215887. No abstract available.

PMID:
23445109
42.

ERBB2 inhibition and heart failure.

Cote GM, Sawyer DB, Chabner BA.

N Engl J Med. 2012 Nov 29;367(22):2150-3. doi: 10.1056/NEJMcibr1203156. No abstract available.

PMID:
23190227
43.

That old devil moon.

Chabner BA.

Oncologist. 2012;17(11):1349-50. doi: 10.1634/theoncologist.2012-0392. Epub 2012 Oct 15. No abstract available.

44.

Patient navigation for underserved patients diagnosed with breast cancer.

Raj A, Ko N, Battaglia TA, Chabner BA, Moy B.

Oncologist. 2012;17(8):1027-31. doi: 10.1634/theoncologist.2012-0191. Epub 2012 Jul 2.

45.

Call it cancer.

Chabner BA, Smith M.

Oncologist. 2012;17(2):149-50. doi: 10.1634/theoncologist.2012-0004. Epub 2012 Feb 2. No abstract available.

46.

Editor's Note ...Clinical Trial Reports: A New Section.

Fojo T, Bates S, Chabner BA.

Oncologist. 2012;17(1):11-2. doi: 10.1634/theoncologist.2012-0040. No abstract available.

47.

Drug shortages--a critical challenge for the generic-drug market.

Chabner BA.

N Engl J Med. 2011 Dec 8;365(23):2147-9. doi: 10.1056/NEJMp1112633. Epub 2011 Oct 31. No abstract available.

PMID:
22040167
48.

Self-plagiarism.

Chabner BA.

Oncologist. 2011;16(10):1347-8. doi: 10.1634/theoncologist.2011-0312. No abstract available.

49.

Patient navigator programs, cancer disparities, and the patient protection and affordable care act.

Moy B, Chabner BA.

Oncologist. 2011;16(7):926-9. doi: 10.1634/theoncologist.2011-0140.

50.

It is time to include patients with brain tumors in phase I trials in oncology.

Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, Grossman SA, Prados MD, DeAngelis LM.

J Clin Oncol. 2011 Aug 20;29(24):3211-3. doi: 10.1200/JCO.2011.36.6328. Epub 2011 Jul 18. No abstract available.

Supplemental Content

Loading ...
Support Center